Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
治疗性PD-L1抗体在阻断PD-1 / PD-L1信号传导方面比PD-1抗体更有效。
Scientific Reports ( IF 3.8 ) Pub Date : 2019-08-07 , DOI: 10.1038/s41598-019-47910-1 Annika De Sousa Linhares 1 , Claire Battin 1 , Sabrina Jutz 1 , Judith Leitner 1 , Christine Hafner 2, 3 , Joshua Tobias 4 , Ursula Wiedermann 4 , Michael Kundi 5 , Gerhard J Zlabinger 6 , Katharina Grabmeier-Pfistershammer 6 , Peter Steinberger 1
Scientific Reports ( IF 3.8 ) Pub Date : 2019-08-07 , DOI: 10.1038/s41598-019-47910-1 Annika De Sousa Linhares 1 , Claire Battin 1 , Sabrina Jutz 1 , Judith Leitner 1 , Christine Hafner 2, 3 , Joshua Tobias 4 , Ursula Wiedermann 4 , Michael Kundi 5 , Gerhard J Zlabinger 6 , Katharina Grabmeier-Pfistershammer 6 , Peter Steinberger 1
Affiliation
|
PD-1信号抑制剂已彻底改变了癌症治疗方法。PD-1和PD-L1抗体已被批准用于治疗癌症。迄今为止，尚未在功能测定中比较治疗性PD-1抑制剂。我们使用了高效的T细胞报道分子平台来评估五种临床上使用的PD-1抑制剂阻断PD-1信号传导的功效。尼古鲁单抗和派姆单抗的半数最大有效浓度（EC50）分别为76.17 ng / ml（95％CI 64.95-89.34 ng / ml）和39.90 ng / ml（34.01-46.80 ng / ml）。PD-L1抑制剂的EC50值对于atezolizumab为6.46 ng / ml（5.48-7.61 ng / ml），6.15 ng / ml（5.24-7.21 ng / ml）和7.64 ng / ml（6.52-8.96 ng / ml） ，avelumab和durvalumab。综上所述，
"点击查看英文标题和摘要"
更新日期：2019-08-07
"点击查看英文标题和摘要"
京公网安备 11010802027423号